varies from 3.6 to 6.0 per 100 000 person-years [2] . Of further concern, MRSA strains are now evolving additional resistances against standard-of-care (SOC) antibiotics [3] . This high unmet clinical need and associated healthcare costs [4] underscore the need for new therapeutic alternatives to treat MRSA infections.
Emerging options for treating gram-positive bacterial infections are lysins [5] . In the natural setting, these bacteriophage-encoded hydrolytic enzymes liberate progeny phage from infected bacteria by degrading peptidoglycan from inside the cell, causing lysis of the host bacterium. Therapeutically, lysins are being developed as antimicrobial agents to lyse pathogenic bacteria by attacking peptidoglycan from outside the cell [6, 7] . The efficacy of lysin therapy has been demonstrated in rodents with experimental pharyngitis [7] , pneumonia [8] , otitis media [9] , abscesses [10] , bacteremia [11] , endocarditis [12] , and meningitis [13] . In addition, lysins are generally highly specific for bacterial species and rarely lyse nontarget organisms, including commensal gut bacteria, which may be beneficial in maintaining gastrointestinal homeostasis [14, 15] .
CF-301, also referred to as PlySs2, was identified as an antistaphylococcal lysin encoded within a prophage of the Streptococcus suis genome [16] . It has a domain arrangement characteristic of most bacteriophage lysins, defined by a catalytic N-terminal domain linked to a cell wall-binding C-terminal domain [5] ( Figure 1A ). The N-terminal domain belongs to the cysteine-histidine-dependent amidohydrolases/peptidases (CHAP) family [20] , common among lysins and other bacterial cell wall-modifying enzymes. The C-terminal domain belongs to the SH3b family [21] that often forms the cell wall-binding element of lysins. Unlike most recombinant lysins that digest S. aureus, which are often poorly expressed and display low solubilities [22] [23] [24] , recombinant CF-301 is highly expressed in E. coli within the soluble fraction [16] .
In the present study we show that CF-301 differs from SOC antibiotics by its potency, speed, specificity, and activity against antibiotic-resistant strains. We also demonstrate a low resistance profile, anti-biofilm activity, and synergy with antibiotics in vitro. Furthermore, we show that CF-301 significantly enhances SOC antibiotic activities against staphylococcal-induced murine bacteremia under challenging conditions where high doses of single antibiotics fail, underscoring the effectiveness of the combination strategy for treating bacteremia.
METHODS

Bacterial Strains and Growth Conditions
Bacterial strains were maintained on BBL Trypticase Soy Agar II with 5% sheep blood (Becton, Dickinson and Company) at 37°C in ambient air. Liquid growth media was Mueller Figure 1 . General features of CF-301. A, Protein sequence and diagrammatic representation of CF-301 depicted with the N-terminal cysteine-histidinedependent amidohydrolases/peptidases (CHAP) domain in blue and the C-terminal SH3b domain in green. The CHAP domain active-site residues (Cys 26 , His 102 , Glu 118 , and Asn 120 ) identified by homology to Protein Data Bank (PDB) entry 2K3A [17] are highlighted in red. B, Ribbon representation of a CF-301 model built with the I-TASSER server [18] using PDBs 2K3A and 1R77 as templates for the N-terminal and C-terminal domains, respectively, with the side chains of the active site residues depicted. The coloring scheme is the same as in panel A. The model was rendered in PyMOL [19] . C, The lytic activity of Escherichia coli expressing CF-301 (compared to a vector control) shown on a lawn of Staphylococcus aureus MW2. D, Sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis of CF-301 (lane 2). Molecular weight markers (PAGE Ruler, Thermo Scientific; lane 1); CF-301 (lane 2). E, Time course of CF-301 lytic activity against S. aureus MW2. Exponential phase cells were treated with either CF-301 (128 µg/mL) or buffer. The OD 600 values were recorded every 30 seconds for 15 minutes. A decrease in optical density was associated with bacteriolysis.
derivative of strain MW2 (NRS 123). Strains CFS738, CFS832 and CFS544 correspond to MRSA strains NRS192, NRS61 and ATCC 25923 respectively.
MIC Determinations
MIC values for CF-301 and comparator antibiotics were determined in triplicate by broth microdilution [25] . Bacteria were suspended in growth media ( 
Statistical Methods
Statistical analysis was performed using the GraphPad Prism 5 software package. Time-kill experiments were analyzed by 2-tailed unpaired Student t test. Results are presented as mean ± SEM. Actuarial mouse survival was analyzed using the log-rank (Mantel-Cox) test. P < .05 was considered statistically significant.
RESULTS
Modeling and Preparation of Lysin CF-301
A CF-301 homology model was built in silico and Figure 1B indicates the location of the CHAP domain active site residues [17] . Escherichia coli clones expressing recombinant CF-301 Yeiled a pronounced lytic zone on agar plates overlaid with live S. aureus cells ( Figure 1C ). The CF-301 protein is 26 kDa with an isoelectric point of 9.15. Conditions to efficiently produce and purify CF-301 at high Yieled (>9 g/L) were developed (Supplementary Methods). The purified lysin ( Figure 1D ) was bacteriolytic against S. aureus cells in a lytic assay in vitro ( Figure 1E ).
CF-301 Is Active Against a Narrow Range of Bacterial Species Including Multidrug-Resistant Strains of S. aureus
CF-301 demonstrated potent inhibitory activity on 250 S. aureus strains tested, including 103 methicillin-sensitive S. aureus (MSSA) and 120 MRSA (Table 1) . It was also active The antibiotic resistance profile of each Staphylococcus aureus group and the molecular weight of each drug are shown. The minimum inhibitory concentrations at which 90% of the isolates (MIC 90 ) were inhibited are shown in µg/mL. The correspond µM values are shown as well.
Abbreviations: mw, molecular weight; DRSA, daptomycin-resistant S. aureus; LRSA, linezolid-resistant S. aureus; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; mw, ; VRSA, vancomycin-resistant S. aureus.
against 54 Streptococcus pyogenes, 51 Streptococcus agalactiae, and 10 Staphylococcus lugdunensis strains (Supplementary Table 1 ). Little or no activity was observed against the other gram-positive or gram-negative bacteria tested. CF-301 inhibited growth of MRSA strains additionally resistant to vancomycin, daptomycin, or linezolid. Shown in Table 1 , CF-301 inhibited the growth of 27 multidrug-resistant strains tested. On a molar basis, CF-301 was 2-to 40-fold more potent than the SOC antibiotics tested.
CF-301 Kills S. aureus Rapidly In Vitro
Time-kill assays [26] were used to test the rate of antimicrobial activity in vitro. CF-301 and SOC antibiotics at their minimum inhibitory concentrations (1× MIC) were tested against 20 MSSA and 42 MRSA laboratory strains. CF-301 reached bactericidal levels (≥3-log 10 CFU reduction [26] ) within 30 minutes against both MSSA and MRSA (Figure 2A and 2B). In contrast, daptomycin required 6 hours to reach similar levels against MSSA and MRSA whereas vancomycin achieved only a 2-log 10 kill in the same time frame. Oxacillin, when tested on MSSA, also demonstrated a 2-log 10 kill requiring 6 hours.
Time-kill experiments were also performed with CF-301 against contemporary strains of 15 MSSA and 15 MRSA ( Figure 2C ), demonstrating rapid bactericidal activity of CF-301 on recent clinical isolates. Potent activity of CF-301 was further illustrated by electron microscopy, where bacteriolysis was observed within 15 seconds of treatment ( Figure 2D and 2E). The speed of the CF-301 lytic activity is consistent with a bactericidal effect that occurs upon contact.
CF-301 Kills S. aureus Rapidly In Vivo
CF-301 exhibited a dose-response curve in treating murine MRSA-induced bacteremia. Measurable enhancement of survival occurred with 0.25 mg/kg CF-301, whereas a high level of protection (70%) was observed with 5 mg/kg ( Figure 3A) .
Rapid bactericidal activity of CF-301 was also demonstrated in the bloodstream. MRSA CFU were measured in the blood of infected mice before and after treatment with CF-301 ( Figure 3B ). Treatment with CF-301 at 2 hours postinfection produced a decrease of 0.5-log 10 CFU within 15 minutes and a 2.0-log 10 decrease in 60 minutes. CF-301 Is Active Against S. aureus Biofilms CF-301 was compared to SOC antibiotics for the ability to eradicate S. aureus biofilms. MRSA ATCC BAA-42 biofilms were grown for 24 hours in polystyrene dishes and subsequently treated with CF-301 (1× MIC) or with daptomycin, vancomycin, or linezolid (1000× MIC each). Following treatments for 2 or 4 hours, residual biofilms were visualized by staining with crystal violet. As shown in Figure 3C , CF-301 at 1× MIC removed all visual biomass by 2 hours, whereas the SOC antibiotics at 1000× MIC failed to remove biomass after 4 hours of treatment.
Resistance of S. aureus to CF-301 Is Low Relative to Resistance to Antibiotics MRSA MW2 was serially passaged in the presence of increasing amounts of CF-301. After 26 days of passage, resistance to CF-301 increased no more than 4 times the initial MIC (redcolored datasets, Figure 3D and 3E ). Similar methods were used to detect resistance to SOC antibiotics. Following 26 days of passage in increasing amounts of antibiotics, resistances of 128 and 16 times the initial MIC were observed for daptomycin and vancomycin, respectively ( Figure 3D and 3E) . Figure 3D and 3E ). In contrast to the relatively high resistance levels observed when these SOC antibiotics were tested as single agents, growth of bacteria in antibiotics in the presence of CF-301 resulted in only a 4-fold increase in their resistances, demonstrating that growth of MRSA with CF-301 suppressed formation of antibiotic resistances to both vancomycin and daptomycin.
CF-301 Synergizes With Antibiotics In Vitro
Synergy between CF-301 and SOC antibiotics was assessed using 3 different methods. The first method was the time-kill assay, a preferred technique for examining synergistic antimicrobial activity in vitro [26, 27] . Sub-MIC amounts of daptomycin and 9 CFU (MRSA MW2)/mouse, and blood samples (n = 3 per timepoint) were drawn at various times after CF-301 (or buffer control) treatment and plated for CFU measurements. C, The activity of CF-301 and antibiotics against S. aureus biofilms. D, In vitro selection for decreased susceptibility to CF-301 and/or daptomycin. Over the 26-day passage, the CF-301 minimum inhibitory concentration (MIC) increased from 8 to 32 µg/mL (a 4-fold change) whereas the daptomycin MIC increased from 0.5 to 64 µg/mL (a 128-fold change) without CF-301 and from 0.25 to 1 µg/mL (a 4-fold change) with 1 µg/mL CF-301. E, In vitro selection for decreased susceptibility to CF-301 and/or vancomycin. Over the 26-day passage, the CF-301 MIC increased from 8 to 32 µg/mL (a 4-fold change) whereas the vancomycin MIC increased from 1 to 16 µg/mL (a 16-fold change) without CF-301 and from 0.5 to 2 µg/mL (a 4-fold change) with 2 µg/mL CF-301. Abbreviations: DAP, daptomycin; LZD, linezolid; VAN, vancomycin.
CF-301 were tested individually and found to have minimal kill against MRSA JMI 3345 ( Figure 4A ). However, when the same doses of daptomycin and CF-301 were combined, substantially more effective killing was observed than for either of the individual drugs alone, indicating synergy.
Using the same methodology ( Figure 4B and 4C), 12 additional MRSA strains were tested with sub-MIC daptomycin and sub-MIC vancomycin alone, as well as in combination with sub-MIC CF-301. Synergy was defined as a ≥2-log 10 decrease in CFU/mL [26] at the 6-hour timepoint. Sub-MIC amounts of CF-301 demonstrated synergy when tested in combination with sub-MIC amounts of daptomycin (13/13 strains) and vancomycin (11/13 strains).
A second method to confirm synergy was the checkerboard assay [28, 29] . Checkerboards were generated using combinations of sub-MIC CF-301 with either sub-MIC daptomycin or vancomycin against 26 MRSA and 29 MSSA strains. Synergy was defined as inhibitory activity greater than what would be predicted by adding the 2 drugs together (ie, minimum fractional inhibitory concentration [FIC min ] ≤ 0.5) [28] . With MRSA strains, CF-301 was synergistic with daptomycin (23/26 strains) and vancomycin (18/26 strains). For MSSA, CF-301 was In the third method, the extent of synergy between CF-301 and daptomycin was tested in a combination MIC assay by diluting the 2 drugs together to determine the lowest concentration of the drug combinations required to inhibit growth ( Figure 4D ). Daptomycin alone inhibited growth of MRSA ATCC BAA-1720 at 1.0 µg/mL. In combination with sub-MIC CF-301, the amount of daptomycin required for inhibition decreased to 0.0075 µg/mL. This demonstrated synergy between CF-301 and daptomycin, with a 128-fold decrease in the amount of daptomycin required to inhibit growth. In subsequent studies using the identical format, mixtures of CF-301 and daptomycin were tested on 11 additional MRSA strains, with similar daptomycin susceptibility enhancements observed, ranging from 64-to 256-fold (data not shown). These results confirmed the findings in Figure 4D , underscoring the consistency of the synergistic effect.
CF-301 Accelerates Antibiotic Binding to the Bacterial Cell Wall and Membrane
Antibiotic binding to bacteria was performed with BODIPY-FL-labeled SOC antibiotics in the presence or absence of sub-MIC levels of CF-301. In the presence of CF-301, BODIPY-FL-labeled daptomycin stained S. aureus within 15 minutes, whereas without CF-301, no staining was observed ( Figure 4E) .
In a time-course analysis, BODIPY-FL-labeled vancomycin stained S. aureus within 5 minutes in the presence of sub-MIC CF-301 ( Figure 4F ). In contrast, staining required 30 minutes in the absence of CF-301. The confocal microscopic analysis demonstrated that labeled antibiotic was first observed at the bacterial division plane.
Accelerated staining with antibiotic is further illustrated in a video (Supplementary Video 1) , where in the course of a 2-hour period, BODIPY-FL-labeled daptomycin bound much more rapidly to S. aureus in the presence of sub-MIC CF-301 compared to the rate of binding in its absence.
Combinations of CF-301 With Antibiotics Are More Efficacious in Treating S. aureus Bacteremia Than Treating With Antibiotics Alone
Mice with staphylococcal-induced bacteremia were treated with CF-301 and SOC antibiotics. In a low-challenge model, mice were inoculated intraperitoneally with 7.5 × 10 6 CFU of MRSA MW2 and treated 4 hours later with CF-301, daptomycin, or a combination of both ( Figure 5A ). At 72 hours, treatment with CF-301 yielded 13% survival, whereas treatment with daptomycin yielded 23% survival. Combination of CF-301 with daptomycin resulted in 73% survival, demonstrating that combination therapy was superior to either drug alone (P < .0001).
To test the robustness of combination therapy, the bacterial inoculum was increased to a point where high doses of SOC antibiotics were minimally efficacious. In this high-challenge model, mice were inoculated intraperitoneally with 1 × 10 9 CFU of MRSA MW2, MRSA CFS738, or MRSA CFS832 and treated 2 hours later with CF-301, daptomycin, or a combination of both ( Figure 5B, 5C, and 5D ). At 72 hours, treatment with CF-301 alone resulted in 17%-50% survival, whereas treatment with daptomycin alone resulted in 7%-31% survival. In contrast to these single-drug treatments, the combination of CF-301 with daptomycin improved survival to 82%-90% (P < .0001).
In another high-challenge study, mice were inoculated with MRSA MW2 and treated 2 hours later with CF-301, vancomycin, or a combination of CF-301 with vancomycin ( Figure 5E ). At 72 hours, treatment with either CF-301 or vancomycin alone resulted in 3% survival. Combination of CF-301 with vancomycin improved survival to 67% (P < .0001).
A high-challenge study was also performed with MSSA CFS544 (Figure 5F ). Mice were inoculated intraperitoneally with 10 9 CFU and treated 2 hours later with CF-301, oxacillin, or a combination of CF-301 with oxacillin. At 72 hours, treatment with either CF-301 or oxacillin alone resulted in 3% survival. In contrast, treatment with the combination of CF-301 and oxacillin improved survival to 30% (P < .0001). Similar enhanced activities of combinations were observed in 10 additional MRSA-induced bacteremia experiments (Supplementary Table 2 ). Together with the 16 individual experiments used to compile the graphs shown in Figure 5 , superiority of combination over single-antibiotic treatments was confirmed in 26 independent studies.
DISCUSSION
Antimicrobial drugs used in combination should have complementary and synergistic activities that do not reinforce the liabilities of either drug [30] [31] [32] . Lysins are well suited for use in combinations as their properties uniquely complement those of SOC antibiotics. As illustrated with CF-301, beneficial properties include potent and rapid bacteriolytic effects, activity against drug-resistant strains, narrow specificity, eradication of biofilms, low levels of resistance, and synergy with antibiotics.
Unlike most antibiotics, lysins do not require bacterial metabolism or growth for activity and are bacteriolytic on contact [33] . The rapid CF-301-mediated killing effect was demonstrated in vitro by a >3-log 10 reduction in bacterial viability within 30 minutes of treatment. The rapid-kill property of lysins makes them well suited to quickly reduce the bacterial burden in infected hosts. Although this property can be exploited to rapidly decolonize animals of resident pathogens [7, 10] , the current study with CF-301 focused on systemic treatment. The rapid killing effect was directly demonstrated in vivo by the 2-log 10 drop in pathogen CFU within 1 hour of dosing.
The breadth and potency of CF-301 was demonstrated by its bacteriolytic effect on all 250 S. aureus strains tested, including 120 MRSA and 27 multidrug-resistant strains, and its molar activity being 2-to 40-fold higher than SOC antibiotics tested.
Another beneficial property of lysins is their narrow spectrum of action [5] . Unlike broad-spectrum antibiotics, lysins do not kill beneficial organisms, which should reduce unwanted clinical complications such as Clostridium difficile-associated diarrhea [14, 15] . Whereas combinations of 2 standard broadspectrum antibiotics could be highly disruptive to commensal flora, combinations incorporating a lysin should be preferred owing to their narrow species specificity.
Within infected tissues (eg, heart valves in endocarditis) or prosthetic implants, S. aureus forms biofilms that provide favorable environments for growth and persistence, protecting the pathogen from antibiotics and the immune system [34, 35] . CF-301 has potent activity against S. aureus biofilms and was able to remove biomass at 1× MIC, compared to the activity of SOC antibiotics, which failed to remove comparable biomass at 1000× MIC. Potent antibiofilm activity may be a general feature of the lysin family [36, 37] , and this feature uniquely complements the action of antibiotics by enabling their access to bacteria in disrupted biofilms. We anticipate that combinations incorporating CF-301 may prove efficacious in treating endocarditis and infected implants.
Because of its microbial origin, CF-301 is immunogenic in mammals. However, anti-CF-301 antibodies are nonneutralizing because affinity-purified rabbit anti-CF-301 antisera did not inhibit in vitro lytic activity of CF-301 (data not shown), in agreement with previous studies on antipneumococcal lysin Cpl-1 [11] . Further, immunized mice with anti-CF-301 titers >1:100 000 remained responsive to CF-301 treatment in the murine bacteremia model, indicating that systemic CF-301 treatments may not be appreciably hindered by antibodymediated neutralization or clearance.
Beyond the direct bacteriolytic activity provided by lysins as a single agent, CF-301 also exhibited potent synergy in vitro and significantly improved efficacy in vivo when combined with SOC antibiotics. This agrees with other studies where enhanced activities of lysin/antibiotic combinations have been reported in both in vitro assays [23, 38] and in vivo models [39, 40] . While in vitro synergy between antibiotics and CF-301 was demonstrated here in time-kill and checkerboard assays, it was best illustrated in MIC assays with combined drugs (Figure 4D ). For example, in the presence of low levels of CF-301, the MIC of daptomycin decreased from 1 µg/mL to 0.0075 µg/mL, a 128-fold increase in potency. This powerful synergistic effect was additionally observed with 11 other MRSA strains where CF-301 increased daptomycin potency by 64-to 256-fold.
Fluorescent daptomycin and vancomycin derivatives displayed accelerated binding kinetics to the bacterial envelope in the presence of sub-MIC CF-301. Using similar methodologies, enhanced daptomycin binding to staphylococci has been observed in the presence of nafcillin and attributed to a reduction in net positive cell-wall charge mediated by the β-lactam [41] . In the present study, we propose a different hypothesis to account for the synergy between lysin and antibiotics, whereby at sub-MIC doses of CF-301, a sufficient number of bonds in the peptidoglycan are cleaved, resulting in a more permeable structure, enabling enhanced antibiotic penetration. This hypothesis is supported by preferential antibiotic staining at division septa, where newly formed peptidoglycan is dynamically shaped [42] and appears to be more sensitive to lysin action [33, 43] . Regardless of the mode of action, the in vitro synergy observed is likely to be a key reason for the enhanced efficacy of combinations observed in the animal studies.
Across 26 independent murine staphylococcal-bacteremia studies, multiple variables were examined, including different S. aureus strains (MRSA and MSSA), different bacterial inoculum amounts, and various SOC antibiotics. Invariably, combination treatments of CF-301 and SOC antibiotics significantly outperformed treatments by SOC antibiotics alone.
Although the strength of the bacterial inocula used in the high-challenge models were sufficient to cause failure of highdose treatments of vancomycin or daptomycin (considered to be human-simulated doses [44, 45] ), in all cases the combination treatments were superior. In other MRSA-induced bacteremia experiments, bolus dosing was consistently found to be more efficacious than multiple dosing of the same total amount of CF-301 (ie, twice-or thrice-daily dosing), presumably due to rapid reduction of the bacterial population early in the timecourse of infection. Overall, the in vivo results demonstrate that CF-301 combined with SOC antibiotics is more efficacious than single-drug regimens for treating bacteremia, and that statistically significant results occurred with SOC antibiotics and all S. aureus strains tested.
These results have clinical implications for designing new therapeutic regimens employing combinations of lysins with antibiotics. We envisage an S. aureus bacteremia treatment based on administering a combination of CF-301 and SOC antibiotics. During each round of dosing, the fast-acting CF-301 would rapidly reduce the pathogen burden while the antibiotic would continue to act on residual bacteria. Additionally, synergy between the 2 antimicrobial agents would extend potency and duration of bactericidal action. Advantages of this approach would include limitation of unwanted killing of commensal bacteria due to the narrow-spectrum antimicrobial activity of lysins, and increased exposure and killing of pathogens by antibiotics due to the biofilm-disrupting capacity of lysins. Compared to currently available single-drug options with SOC antibiotics, therapies using lysins in combination with antibiotics should provide unique and efficacious alternatives for treating bacteremia caused by drug-resistant S. aureus.
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